Concept
RAS inhibitors improve clinical outcomes of COVID-19 patients with hypertension
- study reviewed clinical data from medical records of COVID-19 positive hypertensive patients after receiving verbal consent from all patients or patients' family members
- 42 hypertensive patients on antihypertensive therapies of which 17 were on RAS inhibitors and 25 were on other antihypertensive drugs
- ACEI/ARB therapy reduced the inflammatory response, potentially through inhibition of IL-6 levels
- ACEI/ARB therapy also avoided peripheral T cell depletion
- a decrease in viral load from ACEI/ARB therapy was observed but it is hypothesized that RAS inhibitors play an antiviral role by regulating immune function and inhibiting inflammatory responses
0
1
Updated 2021-02-28
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Association study between the use of RAS inhibitors with mortality among patients with hypertension hospitalized with COVID-19
Observational study of hypertension and antihypertensive treatment with COVID-19 mortality
Association study between continued use of RAS inhibitors with clinical outcome
RAS inhibitors improve clinical outcomes of COVID-19 patients with hypertension